D.A. Davidson & Co’s Enanta Pharmaceuticals ENTA Stock Holding History

D.A. Davidson & Co’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,735	Closed	-$58K	–	2371
2016 Q4	$58K	Sell	1,735 -1,010	-37%	-$29K	﹤0.01%	1534
2016 Q3	$73K	Sell	2,745 -819	-23%	-$19K	﹤0.01%	1359
2016 Q2	$78K	Sell	3,564 -611	-15%	-$16K	﹤0.01%	1225
2016 Q1	$122K	Sell	4,175 -5,256	-56%	-$146K	﹤0.01%	1041
2015 Q4	$311K	Sell	9,431 -327	-3%	-$10.7K	0.01%	693
2015 Q3	$352K	Buy	9,758 +9,741	+57,300%	+$418K	0.01%	635
2015 Q2	$0	Buy	+17	New	+$661	﹤0.01%	2216

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

MCM

Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

D.A. Davidson & Co's ENTA Position: Q1 2017 in Review

D.A. Davidson & Co sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 1,735 shares — an estimated $58K sold.

D.A. Davidson & Co first reported a position in ENTA in Q2 2015 and held it in 7 quarters. The position peaked at $352K in Q3 2015. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

D.A. Davidson & Co reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
D.A. Davidson & Co sold 1,735 Enanta Pharmaceuticals shares in Q1 2017, an estimated $58K.
D.A. Davidson & Co first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 7 quarters.
D.A. Davidson & Co's Enanta Pharmaceuticals position peaked at $352K in Q3 2015.
126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on D.A. Davidson & Co's 13F filing for Q1 2017, filed 12 May 2017.